scholarly journals The use of desoxycorticosterone pivalate in dogs with hypoadrenocorticism: a retrospective study of eight cases

2018 ◽  
Vol 87 (6) ◽  
pp. 309-313
Author(s):  
M. Albers ◽  
P. Defauw ◽  
F. Mortier ◽  
S. Daminet

In this article, the use of desoxycorticosterone pivalate is retrospectively reviewed in eight dogs with primary hypoadrenocorticism, presented at the Small Animal Department of Ghent University. The results showed that desoxycorticosterone pivalate provided adequate mineralocorticoid replacement in all cases, also in the dogs that had previously been treated with fludrocortisone acetate. A starting dosage of 1.5 – 2.2 mg/kg SC was used, with a fixed dosing interval of 28 days in most of the cases. Each time, prednisolone was added to the therapy as glucocorticoid supplementation. No side effects related to desoxycorticosterone pivalate therapy were noted and all owners were satisfied with the treatment consisting of desoxycorticosterone pivalate and prednisolone.

2016 ◽  
Vol 43 (8) ◽  
pp. 1547-1552 ◽  
Author(s):  
Alexis Régent ◽  
Serge Redeker ◽  
Alban Deroux ◽  
Pierre Kieffer ◽  
Kim Heang Ly ◽  
...  

Objective.To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA).Methods.A retrospective multicenter study that included 34 patients receiving TCZ for GCA.Results.TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months.Conclusion.TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.


2004 ◽  
Vol 62 (2b) ◽  
pp. 391-395 ◽  
Author(s):  
Rosana Carandina-Maffeis ◽  
Anamarli Nucci ◽  
José F.C. Marques Jr ◽  
Eduardo G. Roveri ◽  
Beatriz H.M. Pfeilsticker ◽  
...  

We analyzed the experience of Unicamp Clinical Hospital with plasma exchange (PE) therapy in myasthenia gravis (MG). About 17.8 % of a totality of MG patients had PE performed: 26 cases, 19 women and seven men. The mean age-onset of MG was 28 years, extremes 11 and 69. Minimum deficit observed in the group was graded IIb (O & G) or IIIa (MGFA scale). One patient had prethymectomy PE. In seven the procedures were performed due to myasthenic crisis and in 18 patients due to severe myasthenic symptoms or exacerbation of previous motor deficit. Two patients were also submitted to chronic PE considering refractoriness to other treatments. Twenty-six patients had 44 cycles of PE and 171 sessions. The mean number of sessions was 3.9 (SD ± 1.4) each cycle; median 5, extremes 2 and 6. The mean time by session was 106,5 minutes (SD ± 35.2); median 100.5 (extremes of 55 and 215). The mean volume of plasma exchanged in each session was 2396 ml (SD ± 561); median 2225 (extremes 1512 and 4500). Side effects occurred: reversible hypotension (seven cases), mild tremor or paresthesias (seven cases). Infection and mortality rates due to PE were zero. All patients had immediate benefit of each PE cycle and usually they also received prednisone or other immunosuppressors. Good acceptance of the procedure was observed in 80.7% of patients.


2021 ◽  
pp. 143-145
Author(s):  
Ana Catarina Viana Valle ◽  
Aloísio Cunha de Carvalho

Introdution: Anal fistula/perianal is a disease that affects the anal tissue and adjacent skin, associated with severe skin infections. The occurrence of this disease is higher than it appears in the routine of the small animal clinic. The etiology of the perianal fistula has not been elucidated so far. The diagnosis is clinical, and its treatment employs antibiotics, immunosuppressants. However, these medicines are not always efficient, and surgery becomes the only option. Side effects are frequent, and a complementary treatment plan must be evaluated. Homeopathy is a therapeutic technique suggested by the German physician Samuel Hahnemann and aims at healing through stimuli to the body's vital energy. This study aimed to report a perianal fistula occurrence in a dog of the French bulldog breed treated by homeopathy. Methods: Male dog, French bulldog breed, with the complaint of walking and sitting at all times associated with the frequent licking of the anus. After physical examination the diagnosis was perianal fistula. The treatment was based by -9 -6 homeopathy with injectable medicines Belladonna D9 (1x10 ) associated with Arnica montana D6 (1x10 ); Nitric acidum -60 -18 30CH (1x10 ); Hamamellis virginiana D18 (1x10 ). The patient showed clinical improvement right after the first application of the medication, decreasing the stimulus of pain and discomfort. Seventeen days after treatment initiation, the inflammatory process was resolved. Homeopathy has been proposed as a regulatory therapy with a natural tendency to rebalance vital energy and organic functions. The homeopathic medicines were chosen based on the law of similars, i.e., using highly diluted and energized medicines to treat the symptoms and diseases that these same substances, in ponderal doses, would cause in a healthy patient. The treatment here reported did not generate side effects and was effective in its purpose. Treatment time was short, and, additionally, the animal was followed up for eight months after treatment with no relevant clinical changes. Conclusion: The therapeutic protocol determined reestablished the function of the affected tissues with total resolution of the disease in 17 days, with no complications. New comparative and randomized studies must be carried out to better understand the efficacy of such therapy


2021 ◽  
Vol 33 (3) ◽  
pp. 200
Author(s):  
Oki Suwarsa ◽  
Fatima Aulia Khairani ◽  
Syawalika Ulya Isneny ◽  
Erda Avriyanti ◽  
Hartati Purbo Dharmadji ◽  
...  

Background: Methotrexate (MTX) and cyclosporine have been used as effective systemic mono-therapy for psoriasis. Several factors are considered to switch monotherapy to combination therapy because monotherapy is no longer effective and has higher side effects. Hence,clinicians have avoided systemic therapy combinations due to its toxicity. However, some studies showed that this combination therapy could be usedeffectively for psoriasis patients. Purpose: This study aimed to analyze the efficacy and adverse effects of systemic MTX and cyclosporine combination therapy in Indonesian psoriasis vulgaris patients. Methods: The retrospective study assessed the effectiveness of 3 monthsmono-therapyand combination therapy of systemic MTX and cyclosporine in psoriasisvulgaris patients from 2016–2017 in Dermatology Clinic, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia. Result: Psoriasis area and severity index (PASI) score 90 were achieved in the group MTX (50%) and cyclosporine group (50%), while none in the combination group.However, eight patients (50%) in group MTX and cyclosporine reached the primary endpoint of PASI 50. One patient in cyclosporine group had adverse effects on kidney profiles. Nonetheless, other patients had no biochemical changes. But, there was no significant difference in the change of PASI between each group (p=0.102). Conclusion: We propose that combination therapy of MTX and cyclosporine is relatively safe and efficacious in treating Indonesian psoriasis vulgaris patients. This combination treatment isas effective as MTX or cyclosporinemono-therapy.


2020 ◽  
Vol 10 (2) ◽  
pp. 47
Author(s):  
Giovanni Pallio ◽  
Natasha Irrera ◽  
Alessandra Bitto ◽  
Federica Mannino ◽  
Letteria Minutoli ◽  
...  

Precise tacrolimus treatment in transplanted patients is achieved in the clinical setting by performing therapeutic drug monitoring (TDM) and consequently adjusting therapy. The aim of this study was to retrospectively analyze the variability in tacrolimus blood levels throughout 2 years of observation in 75 transplanted patients and to investigate if tacrolimus blood levels correlate with presence of genetic polymorphisms, thus modifying tacrolimus pharmacokinetics. CYP3A5*1 (G6986A), CYP3A4*1B (A392G), CYP3A4*22, ABCB1 (C3435T; C1236T; G2677A/T), SLCO1B1 (T521C), polymorphisms were analyzed. Based on the effect of their genotypes, patients were stratified into 5 groups: (1) reduced tacrolimus metabolism (RM), (2) increased metabolism (IM), (3) transporters polymorphisms (TM), (4) metabolism and transporter polymorphisms (AM) and (5) no mutations (Wild Type, WT). The percentage of the samples out of therapeutic range was significantly higher in the IM group than in the WT group (p = 0.001), as well as compared to the TM group (p = 0.004). Only IM pattern (p = 0.015) resulted as an independent predictor of number of tacrolimus blood levels out of therapeutic range. RM pattern (p = 0.006) was inversely related to the administered dose. Therefore, genotyping could become a standard practice before tacrolimus prescription thus decreasing side effects, increasing efficacy and reducing the economic burden for the national health system.


2019 ◽  
Vol 5 (1) ◽  
pp. e000609
Author(s):  
Chelsea Oester ◽  
Alexis Weber ◽  
Martin Vaso

ObjectiveExamine the intake of medication and supplements used by top-level players during the 2018 FIFA World Cup Russia.Participants736 top-level playersSettingThe team doctors uploaded a list of the medications used by each player to the online reporting tool within 72 hours of each match of the 2018 FIFA World Cup Russia.Outcome measuresAverage number of medications used per player per match and during the tournament; average number and percentage of players using at least one medication per match and during the tournament.Results54% of the players took at least one medication during the tournament and 39% took at least one medication before each match. The most used medications were non-steroidal anti-inflammatory drug (NSAID) (38.6%), followed by other analgesics (13.8%) and medications for insomnia and anxiety (13%). On average, 0.72 medications were taken per player per match and 1.32 per player during the tournament. The mean number of medication intake per player per match was higher during the knockout stage compared with the group stage (0.88±1.36 vs 0.65±1.08, p<0.001). Players from South America and North and Central America took more medications per match compared with the players from Africa (0.9±1.14 and 0.98±1.1 vs 0.48±0.83, p<0.001 in both cases).ConclusionThe intake of NSAIDs decreased during the 2018 FIFA World Cup compared with previous FIFA World Cups, but stayed at a high level. The high number of medications taken is a cause for concern, and therefore, players, medical staff and coaches should be made more aware of the possible side effects of a high medication intake.


2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Elizabeth H. Harman Crowell ◽  
Alexander M. Crowell ◽  
Regan N. Theiler

Sign in / Sign up

Export Citation Format

Share Document